Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Pembrolizumab + Axitinib for Advanced Renal Cell Carcinoma

Apr 22, 2019, 10:08 AM
URL:
On April 19, the FDA approved pembrolizumab (Keytruda, Merck & Co. Inc.) plus axitinib (Inlyta, Pfizer Inc.) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Read the full FDA press release here.

Posted 4/22/2019

Leave a comment